Allergan, Inc.

Aclaris Therapeutics, Inc.

Epi Health, LLC

Vicept Therapeutics, Inc.

Stuart D Shanler

Christopher Powala

Andrew Ondo

Marc Barry Brown

Michael A Botta

Charles Rodney Greenaway Evans

Christopher Phillips

Thomas Nagler

Brian Beger

Sian Tiong Lim

Luis Rios

The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms ofselected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient.

Pharmaceutical cream compositions of oxymetazoline and methods of use

Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts,accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

Peroxide formulations and methods and applicators for using the same

Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an &#x3b1; adrenergic receptor agonist selected from selective &#x3b1;adrenergic receptor agonist, selective &#x3b1;adrenergic receptor agonist, non-selective &#x3b1;/&#x3b1;adrenergic receptor agonist, agents with &#x3b1;adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.

Compositions and methods for treating purpura

The present invention provides pharmaceutical cream compositions comprising oxymetazoline and methods for treating rosacea and other skin disorders as described herein using the above cream compositions.

Pharmaceutical cream compositions and methods of use

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using &#x3b1;-adrenergic receptor (&#x3b1;-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.

Growing community of inventors

Malvern, PA, United States of America

Stuart D Shanler